In this case study, Pharma IQ gains insight from Oxford BioMedica - a pioneer in the development of gene therapies for 20 years, focused mainly on lentiviral vectors. The ebook evaluates manufacturing trends, preparing for the commercial phases of gene therapies, combating extractables and leachables and scaling up.
Please note: That all fields marked with an asterisk (*) are required.
*Processing your payment may take a moment. Please click submit payment only once, and do not refresh this page. Doing so may result in your credit card being charged more than once.
Your experience on this site will be improved by allowing cookies.